Imagine a quick blood sugar test, but for the trillions of tiny microbes living in your body or a vat of wine. Instead of sending samples to a lab and waiting days, this tool gives a full picture of the microbial community in just 10 minutes. It's like having a high-tech microscope and a lab analyst shrunk down into a small, portable device.
Current microbiota analysis is too slow, expensive, and requires lab environments, making it impossible to use for urgent medical decisions during childbirth or real-time quality control in organic food production.
A compact, automated micro-nano-bio platform that provides comprehensive microbiota results in 10 minutes, specifically tailored for vaginal health and beverage fermentation.
If you are a maternity clinic dealing with the risk of mother-to-newborn infections — this project developed a vaginal microbiota test that can prevent up to 59% of childbirth-related infections in the EU.
If you are an organic beverage producer dealing with spoilage due to lack of chemical preservatives — this project developed a fermentation monitoring tool that can reduce spoilage rates by 5–25%.
If you are a wellness provider dealing with the need for real-time health data — this project developed a rapid microbiota analysis platform that allows consumers to make immediate decisions based on their microbial balance.
Based on available project data, the specific price per test is not listed, but the project objective is to make microbiota analysis 'affordable' compared to current slow and costly methods.
The project is currently maturing the technology from TRL4 to TRL6, meaning it is moving from a laboratory prototype toward a demonstrated system in a relevant environment.
The solution is supported by 21 patents, providing a strong competitive advantage in the microbiota market.
The project targets regulated healthcare markets and aims to move beyond standard Group B Streptococcus screening to improve childbirth outcomes.
The project period runs from 2024-03-01 to 2026-06-30, with the goal of reaching TRL6 by the end of the term.
The project is led by a single French SME, BforCure, which represents 100% of the consortium. This structure indicates a highly agile, industry-driven approach with a focus on rapid commercialization, leveraging the company's previous success in bringing a microfluidic medical device to market in 3 years.
Contact BforCure in France for licensing or partnership opportunities regarding the RAMAN platform.
Contact SciTransfer to explore integration of RAMAN technology into your diagnostic or food quality pipeline.
